Selinexor (XPOVIO®)
Multiple Myeloma
Key Facts
About Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage company focused on discovering and developing novel oral cancer therapies targeting nuclear export. Its foundational achievement is the FDA approval of selinexor (XPOVIO®) for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company's strategy leverages its proprietary oral SINE technology platform to expand selinexor into earlier treatment lines and new indications, while developing next-generation compounds like eltanexor and verdinexor to improve tolerability and efficacy. Karyopharm aims to establish XPO1 inhibition as a cornerstone of cancer treatment across a spectrum of malignancies.
View full company profileAbout Karyopharm Therapeutics
Karyopharm Therapeutics is an innovation-driven, commercial-stage company focused on discovering and developing novel oral cancer therapies targeting nuclear export. Its foundational achievement is the FDA approval of selinexor (XPOVIO®) for relapsed/refractory multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company's strategy leverages its proprietary oral SINE technology platform to expand selinexor into earlier treatment lines and new indications, while developing next-generation compounds like eltanexor and verdinexor to improve tolerability and efficacy. Karyopharm aims to establish XPO1 inhibition as a cornerstone of cancer treatment across a spectrum of malignancies.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |